SCHEDULE 13G: Intracoastal Capital and Affiliates Disclose 4.99% Stake in Lixte Biotechnology Holdings

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, has disclosed a beneficial ownership of 4.99% in Lixte Biotechnology Holdings, Inc. common stock.

Summary

• Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC (collectively, the "Reporting Persons") have filed a Schedule 13G disclosing their beneficial ownership in Lixte Biotechnology Holdings, Inc. (the "Issuer").
• As of the close of business on February 17, 2025, the Reporting Persons collectively beneficially own 138,763 shares of Lixte Biotechnology Holdings, Inc. common stock.
• This ownership represents approximately 4.99% of the Issuer's common stock.
• The beneficially owned shares consist of 42,000 shares directly held by Intracoastal Capital LLC and 96,763 shares issuable upon the exercise of Intracoastal Warrant 1.
• The beneficial ownership is capped at 4.99% due to blocker provisions in both Intracoastal Warrant 1 and Intracoastal Warrant 2, which prevent exercise if it would result in ownership exceeding this threshold.
• Without these blocker provisions, the Reporting Persons would have been deemed to beneficially own 261,495 shares of Common Stock as of February 17, 2025.
• The filing stems from a Securities Purchase Agreement (SPA) executed with Lixte Biotechnology Holdings, Inc. on February 11, 2025.

Sentiment

Score: 6

Explanation: The filing indicates a new investment by a group of investors, which can be seen as a positive signal of confidence in the company. However, it's a factual disclosure of ownership, not a performance report, so the sentiment is largely neutral. The strategic capping of ownership at 4.99% is a neutral technical detail.

Positives

• The disclosure indicates a significant investment by a group of investors, potentially signaling confidence in Lixte Biotechnology Holdings, Inc.
• The investment is structured with blocker provisions to strategically manage ownership thresholds, avoiding immediate triggers for higher reporting requirements.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The disclosure of a new significant investor group could influence market perception and potentially share price. The blocker provision ensures the investor group remains below the 5% threshold, which might limit immediate activist concerns.

Key Dates

Keywords

Lixte Biotechnology Holdings, Intracoastal Capital, Mitchell P. Kopin, Daniel B. Asher, Schedule 13G, beneficial ownership, common stock, equity investment, warrant, blocker provision, SEC filing